Details of the Drug

General Information of Drug (ID: DMCEUOH)

Drug Name
Fluoropeptide vaccine
Synonyms FP-01; Fluoropeptide vaccine (influenza); Fluoropeptide vaccine (influenza), Immune Targeting Systems
Indication
Disease Entry ICD 11 Status REF
Influenza virus infection 1E30-1E32 Phase 2 [1]
Drug Type
Vaccine
Cross-matching ID
TTD ID
D0C8AL

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell surface glycoprotein CD4 (CD4) TTN2JFW CD4_HUMAN Not Available [2]
T-cell surface glycoprotein CD8 (CD8) TTMHA6L CD8A_HUMAN; CD8B_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Influenza virus infection
ICD Disease Classification 1E30-1E32
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
T-cell surface glycoprotein CD4 (CD4) DTT CD4 9.36E-04 0.67 2.62
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01703923) An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough. U.S. National Institutes of Health.
2 A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
5 Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62.
6 Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.
7 Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2.
8 Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
9 Clinical pipeline report, company report or official report of ViiV Healthcare.
10 Clinical pipeline report, company report or official report of TaiMed Biologics.
11 Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
12 Clinical pipeline report, company report or official report of TaiMed Biologics.
13 Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6.